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Abstract: Somatostatin-based 
radioligands were shown to have 
sensitive imaging properties for 
neuroendocrine tumours and their 
metastases. The potential of 
[55Co]DOTATOC (DOTATOC = 4,7, 
10-tricarboxymethyl-1,4,7,10-
tetraazacyclododecane-1-yl-acetyl-D-
Phe-Lys-Tyr-D-Trp-Lys-Thr-Lys-1-
threoninol (disulfide bond) as a new 
radiopharmaceutical agent for PET was 
evaluated. 57Co was used as a surrogate 
of the positron emitter 55Co and the 
pharmacokinetics of [57Co]DOTATOC 
was investigated using two nude mouse 
models. The somatostatin receptor 
subtype (sst1-5) affinity profile of 
[natCo]DOTA-TOC was assessed using 
autoradiographic methods on 
membranes transfected with human 
somatostatin receptor subtypes. These 
studies revealed that [57Co]DOTATOC 
is an sst2-specific radiopeptide 
presenting the highest affinity ever 
found for the sst2 receptor subtype. 
The rate of internalisation into the 
AR4-2J cell line also was the highest 
found for any somatostatin-based 
radiopeptide. 
Biodistribution studies, performed in 
nude mice bearing the AR4-2J tumour 
or a transfected HEK-sst2 cell-based 
tumour, showed high and specific 
uptake in the tumour and in other sst 
receptor-expressing tissues reflecting 
the high receptor binding affinity and 
the high rate of internalisation.  
The pharmacologic differences between 
[57Co]DOTATOC and [67Ga]DOTA-
TOC were discussed in terms of the 
structural parameters found for the 
chelate models CoII(DOTA)2- and 
GaIII(DOTA)-, whose X-ray structures 
were determined. Both chelates show 
sixfold coordination in 
pseudooctahedral arrangements. 
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Introduction 
The use of radionuclides in medical fields such as molecular 
imaging and targeted radionuclide therapy is in rapid 
expansion[1, 2]. Radiolabeled bioactive peptides are currently 
being employed in tumour targeting using both Positron 
Emission Tomography (PET) and Single Photon Emission 
Computed Tomography (SPECT)[3-9]. PET is an imaging 
modality with the advantage of high spatial resolution, high 
sensitivity, and the potential of quantification. For these 
reasons it is nowadays considered one of the most powerful 
tools for molecular imaging. Bioactive peptides labelled with 
metallic particle-emitting isotopes, such as 90YIII or 177LuIII, 
allow peptide receptor-mediated radionuclide therapy 
(PRMRT)[10]. 
The first regulatory peptides developed for 
radiopharmaceutical applications have been somatostatin 
analogues, which are being employed in the diagnosis of 
somatostatin receptor-positive tumours when modified with 
the chelator DTPA (diethylenetriaminepentaacetic acid) and 
labelled with the γ-emitter 111In[11]. 
Somatostatin is a tetradecapeptide produced by 
neuroendocrine, inflammatory and immune cells and is 
thought to be an important physiological regulator of 
numerous functions. Its action is mediated by five receptor 
subtypes (sst1-sst5), which belong to the G-protein coupled 
receptor family. All subtype receptors have been found to be 
overexpressed to some degree in different tumours, often 
concomitantly on the same cell[12]. By far most important is 
the overexpression of receptor subtype 2. It is therefore 
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conceivable to search for somatostatin analogues with 
improved affinity to sst2. 
We have developed a DOTA (DOTA = 1,4,7,10-
tetraazacyclododecane-N,N´,N´´,N´´´-tetraacetic acid)-deri-
vatised somatostatin analogue, [DOTA0,Tyr3]-octreotide 
(DOTATOC, Figure 1),[13] which has been successfully 
labelled with radiometals and proven to be useful in different 
areas of diagnostic and therapeutic nuclear oncology[14]. In 
particular the 68GaIII-labelled peptide is currently being used 
in several European centres, affording very sensitive images 
of a variety of human tumours and showing an improved 
diagnostic accuracy, superior to other radiological imaging 
modalities such as [111In]DOTATOC[15]. The 68Ga-
DOTATOC shows approximately 5-fold higher binding 
affinity to sst2 than [111In/90Y]DOTATOC ; in addition, it 
shows a higher rate of internalisation into sst2-expressing 
tumour cells, an approximately 2.5-fold higher tumour uptake 
and a significantly lower kidney uptake in animals and 
patients. We have previously shown that this difference in the 
biological behaviour of metallopeptides may be attributed to 
structural differences within the chelate moiety[13, 16].  
((Insert Figure 1 here)) 
Figure 1. Structural formulae of [DOTA0,Tyr3]-octreotide (DOTATOC) (above) and. 
DOTA-D-PheNH2 (below).  
A crystallographic study of the GaIII- and YIII-chelates of 
the model peptide DOTA-D-PheNH2 (Figure 1) showed 
differences in their geometry. GaIII(DOTA-D-PheNH2) is 
hexacoordinated with pseudooctahedral cis-geometry and a 
folded macrocyclic unit whereas the structure of YIII(DOTA-
D-PheNH2) has eight-fold coordination including the amide 
carboxy oxygen with a somewhat distorted square-
antiprismatic geometry. Distant from the pharmacophore of 
the molecule, this structural difference within the metal 
chelate leads to a five times higher receptor affinity and 
probably is also responsible for the mentioned improved 
biodistribution of the radiogallium-labelled compound. This 
superiority could also be confirmed clinically using 
[68Ga]DOTATOC in PET[17] and [67Ga]DOTATOC in 
SPECT[13, 18]. This finding prompted us to exploit such 
structural features when using another positron-emitting 
metal, namely 55CoII (t1/2 17.5 h, β+ (77%), EC (23%)). While 
the structures of the GaIII- and CoII-labelled peptides are 
expected to be similar, the use of the longer-lived cyclotron-
produced 55CoII as PET radiometal could allow imaging at 
later time points when target-to-background ratios are higher. 
In the literature there are reports of the use of 55CoII as a PET 
radiometal in medical fields that range from cerebrovascular 
diseases[19-21] to studies of human lymphocyte distribution[22] 
and [55Co]EDTA-based quantitative imaging of the 
kidneys[23]. 
In the present work we used 57CoII (t1/2 270 d, Eγ = 122 
keV (86%), 136 keV (10%)) as a surrogate of 55CoII to study 
the biodistribution of [57Co]DOTATOC in two mouse tumour 
models and also to compare its receptor binding affinity and 
subtype specificity with those of [67/68Ga]DOTATOC and 
[90Y]DOTATOC. In addition, X-ray studies of CoII(DOTA)2- 
and GaIII(DOTA)-, two model chelates with relevance to the 
monoamide structures of the peptide derivatives, were 
performed with the aim of potentially understanding the 
differences and similarities in the biological behaviour of the 
different radiometal-labelled peptides. 
 
Results and Discussion 
Synthesis, labelling and stability: The preparation of 
DOTATOC involves the coupling of the monoreactive 
DOTA(tBu)3-prochelator to the solid phase-assembled, side 
chain-protected peptide, as described in Ginj et al[24]. The 
model DOTA-peptide, DOTA-D-PheNH2, was synthesised in 
a similar way. DOTATOC was labelled with 57CoII in acetate 
buffer (pH 5) by heating (95°C, 30 min); the labelling yield 
was >99.5% at a specific activity of 5 mCi/µmol. 
CoII(DOTA-D-PheNH2)-, CoII(DOTA)2- and GaIII(DOTA)- 
were prepared by adding the ligand and metal chloride or 
nitrate in water and heating (95°C, 30 min). Slow evaporation 
of aqueous solutions of CoII(DOTA)2- and GaIII(DOTA)- 
afforded single crystals suitable for X-ray analysis.  
To understand the pharmacologic differences between 
[67Ga]DOTATOC and [57Co]DOTATOC we set out NMR-
experiments to establish the oxidation state of cobalt in the 
model chelates and in [57Co]DOTATOC. Labelling and 
complexation reactions were performed at elevated 
temperatures and in aerated solution which may cause 
autoxidation of CoII. Cobalt occurs naturally as the 
mononuclear isotope 59Co, which has a nuclear spin I=7/2, a 
relative large nuclear quadrupole moment and its chemical 
shifts in different chemical environments span a range of 
18000 ppm. Contrary to CoIII the CoII ion (d7) is 
paramagnetic and its complexes are therefore beyond the 
scope of 59Co NMR investigation. 
We performed 59Co NMR spectroscopy with the model 
chelate CoII(DOTA-D-PheNH2) and established the absence 
of 59Co NMR signal in a wide spectral window in aqueous 
solution. This is consistent with a +2 oxidation state. In an 
octahedral environment, divalent cobalt may be found in two 
different electronic states: a low spin t2g6eg1 state with one 
unpaired electron (S=1/2) and a high spin state t2g5eg2 with 
three unpaired electrons (S=3/2). The colour of the chelate is 
consistent with a high spin octahedral species, typically pale 
red or purple. Another strong indication for the high spin 
assignment comes from the X-ray structure. Low spin 
octahedral CoII complexes undergo Jahn-Teller distortion. In 
Co-DOTAH2 the equatorial Co-N bond length (2.171 Ǻ) 
differs very little from the axial (2.203 Ǻ). This is contrary to 
the Jahn-Teller distorted Cu-DOTA (Cu-Neq = 2.107 Ǻ; Cu-
Nax = 2.318 Ǻ). 
Temperature-dependent 1H NMR studies of Co-DOTA 
and Co-DOTA-D-PheNH2, in a large spectral window, 
revealed that the number of signals and their width can vary 
significantly, reflecting a combination of paramagnetic shift 
and exchange effects, consistent with a high spin state for the 
CoII ion.  
Our results demonstrate that dioxygen does not oxidise 
these polyamine polycarboxylate cobalt chelates despite the 
fact that the experiments were carried out in aerated solutions. 
This is in accordance with earlier reports that tertiary amine 
ligands stabilise low valent transition metal ions, in particular 
the CoII ion[25, 26]. 
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The thermodynamic stability of CoII-DOTATOC was 
estimated by assessing the thermodynamic stability of the 
model chelate CoII(DOTA-D-Phe-NH2)-. For this purpose we 
performed complexation competition experiments using 
57CoII as radiotracer and DOTA as an auxiliary competing 
ligand. The integration of the HPLC-radiochromatographic 
peaks corresponding to 57/59Co(DOTA)2- and 57/59CoII(DOTA-
D-Phe-NH2)- (Figure 2) remains unchanged after 
equilibration and allows the estimation of the conditional 
stability constant of CoII(DOTA-D-Phe-NH2)- at different pH 
values.  
((Insert Figure 2 here)) 
Figure 2. Typical HPLC-radiochromatogram of a 1:1:1 mixture of 
57,59CoCl2:DOTA:DOTA-D-PheNH2 (0.1 M NaOAc, pH 5.0) after 9 days of incubation 
at RT.  
This method requires the knowledge of the stability 
constant of CoII(DOTA)2- (logKCo(DOTA)=19.9) and of the 
protonation constants of both ligands. Using the relationships 
Kcond=αKML; 
 
)][....][][1( 22111 nn HKHKKHK +++− ++++=α
  
(where K1, K2, Kn are the protonation constants of the free 
ligand); and  
  
 
we were able to estimate the thermodynamic stability 
constant of CoII(DOTA-D-PheNH2)- to logKML=19.6. This 
value shows that the model peptide chelate does not undergo 
a significant loss of thermodynamic stability compared to that 
of CoII(DOTA)2-.  
Potentiometry allowed obtaining the protonation 
constants (pKa´s) of DOTA and DOTA-D-PheNH2; DOTA: 
pK1=12.32(6), pK2=9.73(1), pK3=4.60(1), pK4=4.06(2), and 
pK5=2.08(9); DOTA-D-PheNH2: pK1=11.63(14), 
pK2=9.28(5), pK3=4.18(14), pK4=2.14(16) and pK5<2 (µ=0.5 
M tetramethylammonium nitrate, 25°C). The lower 
protonation constants of DOTA-D-PheNH2, in comparison to 
those of DOTA, arise from the charge difference of the two 
chelators. 
The kinetic stability of [57Co]DOTATOC in regard to 
trans-chelation was evaluated in the presence of 104 times 
excess of DTPA (acetate buffer, pH 5.0). The chemical 
inertness of the radiometal-labelled peptide was also studied 
measuring the isotope exchange rate in the presence of a 104-
fold excess of free 59CoII. The results showed high stability of 
[57Co]DOTATOC over a time interval of 7 days (>98% intact 
radiopeptide).  
In human serum the iron transport protein transferrin can 
bind with high affinity to many metal ions including CoII;[27] 
in this respect it is important to evaluate the kinetic stability 
of radiometal-labelled peptides under physiological 
conditions. For this purpose we measured the rate of 57CoII 
transfer from [57Co]DOTATOC in human blood serum.[28] 
The approximate transfer half-life is 800 h, which compares 
toT1/2=1250 h of [67Ga]DOTATOC[13]. 
Receptor binding assays 
Table 1 shows the IC50 values of CoII-DOTATOC, compared 
to other somatostatin-based metallopeptides for the five 
somatostatin receptor subtypes (sst1-sst5). SS28 
(somatostatin 28) was the control peptide. These values were 
obtained performing a competition experiment with the cold 
59CoII-labelled peptide and the universal somatostatin 
radioligand 125I-[Leu8,D-Trp22,Tyr25]-SS28 on cell 
membranes expressing the different receptor subtypes. CoII-
DOTATOC exhibits circa 6 times higher affinity to sst2 than 
SS28, whereas GaIII-DOTATOC is equipotent and YIII-
DOTATOC has a fourfold lower sst2-affinity than SS28. 
CoII-DOTATOC shows the highest sst2 affinity of any 
somatostatin-based metallopeptide found so far.[12] 
Additionally, CoII-DOTATOC shows also higher affinity to 
sst4 than the other two metallopeptides but a distinctly lower 
sst5 affinity. 
Table 1. Affinity profiles (IC50) for human sst1-sst5 receptors for different somatostatin 
analogues 
Compound sst1 sst2 sst3 sst4 sst5 
SS-28 [a] 5.2±0.3 
(19) 
2.7±0.38 
(19) 
7.7±0.9 
(15) 
5.6±0.4 
(19) 
4.0±0.3 
(19) 
Octreotide [a] >10000 
(5) 
2.0±0.7 
(5) 
187±55 
(3) 
>1000 
(4) 
22±6   
(5) 
YIII-DOTATOC [a] >10000 
(4) 
11±1.7 
(6)  
389±135 
(5)  
>10000 
(5) 
114±29 
(5)  
CoII-DOTATOC >10000 
(5) 
0.44±0.1
1 (5) 
>1000 
(5) 
610±258 
(4) 
440±132 
(5) 
GaIII-DOTATOC [a] >10000 
(6) 
2.5±0.5 
(7) 
613±140 
(7) 
>1000 
(6) 
73±21 
(6) 
[a] data from Reubi et al.[12] 
Internalisation and efflux 
The specific internalisation of [57Co]DOTATOC was 
evaluated using AR4-2J rat pancreatic tumour cells which 
exclusively express sst2. The radiometal-labelled peptide 
showed a time-dependent uptake with a very high specific 
internalisation rate, as shown in Figure 3 (scale of left y-axis 
and lower x-axis). 
((Insert Figure 3 here)) 
Figure 3. Internalisation (triangles; scales on the left side and bottom) and 
externalisation (diamonds; scales on the right side and top) of [57Co]DOTATOC in rat 
pancreatic AR4-2J cells.  
After 6 h [57Co]DOTATOC showed almost 50% specific 
internalisation in 1 million cells, constituting the highest 
internalisation rate ever found for a somatostatin derivative. 
In the same cell line [67Ga]DOTATOC showed an uptake of 
16.5±1% at 4 h p.i.[29]; [57Co]DOTATOC internalised about 
30% at 4 h p.i. whereas [111In]DOTATOC internalised 
11.5±0.7% of the total amount of radiopeptide added to 1 
million cells. In order to evaluate the retention of the 
radiometal-peptide in the tumour cells, externalisation 
experiments were performed also in AR4-2J tumour cells. 
Cells were pre-loaded with [57Co]DOTATOC for 2 h at 37°C. 
To remove the receptor-bound radiometal-peptide an acid 
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wash was carried out twice with a 0.1 M glycine buffer pH 
2.8, 10 min, on ice. Afterwards, externalisation of 
[57Co]DOTATOC was monitored at 30, 60, 120 and 240 min 
at 37°C, as shown in Figure 3 (scale of right y-axis). The 
externalisation results also showed a time dependence: the 
radiometal-labelled peptide presented circa 40% efflux from 
the cells within 4 h.  
Biodistribution in tumour-bearing mice 
For comparative reasons pharmacokinetic studies were 
performed in two mouse models (nude mice bearing the 
AR4-2J or HEK-sst2 tumour [30, 31]. The results are given in 
Tables 2 and 3 and in Figure 4 as % of injected activity per 
gram of tissue (% IA/g).  
((Insert Figure 4 here)) 
Figure 4. Biodistribution of [57Co]DOTATOC in nude mice bearing a tumour (% 
IA/g: % injected activity per gram).  
The radiometal-labelled peptide was cleared rapidly from 
the circulation as demonstrated by the measurement of blood 
samples taken at 4, 24, and 48 hours p.i. (AR4-2J) or 0.5, 1, 
and 4 hours p.i. (HEK-sst2).  
Table 2. Biodistribution of [57Co]DOTATOC in a nude mouse tumour-bearing (AR4-
2J) animal model (4, 24 and 48 h p.i.).  
Organ 4 h 
unblocked 
4 h blocked 24 h 48 h 
Blood 0.03±0.01 0.06±0.03 0.01±0.00 0.01±0.00 
Pancreas 2.81±0.60 0.62±0.31 0.25±0.05 0.11±0.04 
Small intestine 0.69±0.34 0.27±0.11 0.21±0.02 0.08±0.02 
Spleen 0.11±0.22 0.12±0.04 0.07±0.02 0.03±0.00 
Liver 0.20±0.02 0.39±0.13 0.07±0.02 0.07±0.03 
Stomach 5.75±0.80 1.65±0.54 2.56±0.26 1.37±0.33 
Adrenals 2.33±0.54 0.75±0.15 2.20±0.43 1.33±0.41 
Kidneys 9.11±2.24 22.88±6.86 1.24±0.38 1.38±0.65 
Lung 0.34±0.06 0.41±0.15 0.06±0.03 0.05±0.02 
Heart 0.06±0.01 0.07±0.02 0.03±0.01 0.02±0.00 
Tumour 22.81±2.88 8.52±1.71 2.08±0.41 0.70±0.25 
Tumour/non-tumour-ratios 
Tumour/blood 760  208 70 
Tumour/liver 114  397 10 
Tumour/kidney 2.5  2.01 0.51 
 
 Less than 0.15% IA/g remained in blood after 4 h. The 
clearance from all somatostatin receptor-negative tissues 
including the kidneys is also fast. Unexpectedly, also the 
tumour uptake in the AR4-2J tumour decreased between 4 h 
and 24 h by >90%. This was never observed before in any 
somatostatin-based radiopeptide which usually show 
biological half-lives of ≥24 h in tumours of this tumour 
model[30]. The highest tissue activity was found in the 
kidneys, which demonstrates the renal excretion of the 
radiopharmaceutical. At all time points the uptake in other 
organs was considerably lower except for the stomach which 
has been known for its presence of somatostatin receptors. 
Some uptake could be seen in the pancreas and the adrenals 
as well, which was expected since these two organs express 
somatostatin receptors. The pancreas shows a good clearance 
after 24 h whereas the uptake in the adrenals stays relatively 
high (60% of the 4 h value after 48 h). 
Table 3. Biodistribution of  [57Co]DOTATOC in a nude mouse model (HEK-sstr2); 0.5 
h, 1 h, 4 h, 4 h blocking) 
Organ 0.5 h 1 h 4 h 4 h blocking 
Blood 1.56±0.16 0.48±0.23 0.13±0.02 0.12±0.06 
Heart 0.84±0.02 0.32±0.03 0.19±0.01 0.07±0.02 
Liver 1.24±0.05 0.69±0.01 0.40±0.04 0.83±0.11 
Spleen 0.96±0.22 0.67±0.15 0.34±0.04 0.36±0.18 
Lung 2.29±0.17 6.37±2.74 1.24±1.05 0.29±0.06 
Kidneys 16.80±2.20 12.15±2.14 6.48±0.62 8.81±0.73 
Stomach 21.13±9.09 17.10±0.96 8.24±1.29 0.55±0.47 
Intestine 1.88±0.05 2.18±0.63 1.07±0.20 0.21±0.21 
Adrenals 2.78±0.38 1.35±0.08 1.58±0.49 0.18±0.14 
Pancreas 28.86±0.47 15.36±0.54 5.44±2.13 0.34±0.37 
Pituitary 5.80±2.90 9.47±1.93 4.56±2.86 0.25±0.09 
Muscle 0.82±0.70 0.16±0.03 0.07±0.03 0.19±0.29 
Tumour 28.35±2.46 28.97±3.85 34.91±0.23 5.15±0.79 
Tumour/Non-Tumour Ratios 
Tumour/Blood 18 60 278  
Tumour/Liver 23 42 86  
Tumour/Kidney 1.7 2.4 5.4  
A high radioligand accumulation could be measured in 
the tumours four hours after the injection. When the receptors 
were blocked by a simultaneous injection of octreotide the 
accumulation of radioactivity in the tumour was significantly 
reduced by 63%. A higher reduction could be seen in the 
stomach (71%), the pancreas (88%), and the adrenals (68%). 
Upon blocking the accumulation in the kidneys was increased 
by a factor of 2.5. 
In all non-tumour and non-receptor-specific tissues a fast 
clearance of the radiopharmaceutical was observed; this even 
holds for the kidneys (after 48 h 15% of the activity of the 4 h 
value is found in this organ).  
The HEK-sst2 model was used to study the 
pharmacokinetics at shorter time points for comparative 
reasons. The general picture was similar to the other tumour 
model. The tumour uptake was very high, doubling the value 
obtained using another potent sst2-selective radiopeptide, 
[111In]DTPA-TATE (IC50 = 1.3 nM) at 4 h p.i. [31]. Blocking 
was performed by coinjection of 100 µg 
[DOTA,Tyr3,Thr8]octreotide (DOTATATE) and was more 
efficient than the blocking with 50 µg octreotide in the AR4-
2J mouse model. The unspecific level was lowered to 14.7% 
in the tumour, 6.3% in the pancreas and 5.5% in the pituitary. 
The tumour uptake is persistent, even increasing, in the first 4 
h whereas the initial high pancreas uptake is washing out 
relatively fast. The tumour/blood, tumour/liver and 
tumour/kidney ratios increased considerably during the first 4 
hours and a value of 5.4 was never before observed in this or 
a similar tumour model using a somatostatin-based 
radiometallopeptide. 
 Coordination chemical aspects: It is of major 
importance to understand why the radiometal ion influences 
the receptor binding affinity and the tumour uptake. With 
regard to this we crystallised two model chelates, 
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CoII(H2DOTA) and GaIII(DOTA)-, which correspond 
respectively to the metal chelate moieties of CoII-DOTATOC 
and GaIII-DOTATOC, and determined their X-ray structures. 
Both chelates crystallise as diprotonated species. ORTEP 
representations of the chelates are shown in Figures 5 and 6. 
Crystallographic data are summarised in Table 4. 
((Insert Figure 5 here)) 
Figure 5. Ortep plot of the crystal structure of CoII(DOTA)2- (thermal ellipsoids at 50% 
probability level). Selected bond lengths [Å] and angles [°]: Co(1)-N(2) 2.271(6), 
Co(1)-N(2) 2.271(6), Co(1)-N(3) 2.203(6), Co(1)-N(3) 2.203(6), Co(1)-O(5) 2.038(5), 
Co(1)-O(5) 2.038(5); N(2)-Co(1)-N(2) 108.1(3), N(3)-Co(1)-N(3) 154.0(3), O(5)-
Co(1)-O(5) 90.7(3).  
((Insert Figure 6 here)) 
Figure 6. Ortep plot of the crystal structure of GaIII(DOTA)- (thermal ellipsoids at 50% 
probability level). Selected bond lengths [Å] and angles [°]: Ga(1)-N(3) 2.105(9), 
Ga(1)-N(5) 2.116(9), Ga(1)-N(2) 2.116(10), Ga(1)-N(4) 2.187(10), Ga(1)-O(8) 1.940(7), 
Ga(1)-O(12) 1.913(8); N(3)-Ga(1)-N(5) 109.0(2), O(12)-Ga(1)-O(8) 82.39(13), N(2)-
Ga(1)-N(4) 157.1(2).  
Table 4. Crystallographic data of CoII(DOTA)2- and GaIII(DOTA)- chelates 
 CoII(H2DOTA) GaIII(H2DOTA)+Cl- 
chem. formula C16H26CoN4O8 C16H26ClGaN4O8.5H2O 
fw 461.34 597.65 
cryst. size /mm 0.6x0.6x0.4 0.5x0.5x0.5 
space group Pccn CC 
cryst. syst. orthorhombic monoclinic 
a/Å 15.225 (3) 15.171,90 
b/Å 9.3920 (19) 14.962,94.10 
c/Å 13.065 (3) 10.068,90 
V/Å3 1868.2 (6) 2279.5 
Z 4 4 
ρcalcd/g cm-3 1.640 1.706 
T/K 183(2) 183(2) 
µ/mm-1 0.974 1.400 
λ Å 0.71073 (Mokα 0.71073 (Cukα  
 
  The structures of the CoII- and GaIII-DOTA chelates are 
very similar showing six-coordination and a 
pseudooctahedral geometry. Axially, two macrocyclic ring 
nitrogens and two trans-arranged carboxylate oxygens are 
bound whereas the remaining two ring nitrogens form 
equatorial bonds to the metals. The deviation from the 
octahedron is seen in the equatorial N-M-N bond angles 
(180° in a regular octahedron) of 154° and 157° for 
CoII(H2DOTA) and GaIII(H2DOTA)+, respectively. Table 5 
shows some selected bond lengths, angles and planes of both 
chelates. The two structures are almost identical and close to 
the corresponding structure of GaIII(DOTA-D-PheNH2)[13] 
showing the relevance of the structures to the monoamide 
peptide derivatives. In both structures, as in GaIII(DOTA-D-
PheNH2), the macrocyclic unit adopts a 2424 conformation. 
The somewhat smaller bond lengths in GaIII(H2DOTA)+, 
relative to CoII(H2DOTA), are compatible with a metallic 
centre of higher charge density (ionic radius of Ga3+=62 pm; 
ionic radius of Co2+high spin=73.5 pm). 
 Table 5. Selected average bond lengths [Å], angles [°] and planes of CoII(DOTA)2-and 
GaIII(DOTA)-chelates. 
 
 
CoII(H2DOTA) GaIII(H2DOTA)+ 
CN [a]  6 6 
Ring config.  2424 2424 
M-N [Å] eq 2.171 (6) 2.111 (8) 
 ax 2.203 (6) 2.152 (50) 
N-M-N [°] eq 154.0 (3) 157.1 (2) 
 ax 108.1 (3) 109.0 (2) 
O-M-O [°] eq 90.7 (3) 82.39 (2) 
M-O [Å] eq 2.038 (5) 1.927 (19) 
DN2O2 [Å]  0.037 0.068 
RN2O2 [Å]  0.08 0.005 
[a] CN is the coordination number of the metal ion, DN2O2 is the distance to the plane, 
RN2O2 is the distance of the defining atoms to the best plane (PN2O2). 
Like in GaIII(DOTA-D-PheNH2)[13], GaIII(H2DOTA)+ and 
CoII(H2DOTA) only show coordination of two acetate groups 
whereas the remaining two are free and one of them will 
always be used when the chelator is coupled to a biomolecule 
forming an amide bond. The similar structural features of 
CoII(H2DOTA) and GaIII(H2DOTA)+ allow the assumption 
that [57Co]DOTATOC and [67Ga]DOTATOC might also have 
similar structures and consequently one would expect the two 
radiopeptides to have similar biological behaviour. The fact 
that in both radiopeptides one carboxylate group is free and 
deprotonated at physiological pH contributes to their fast and 
efficient clearance through the kidneys. Despite the likely 
structural similarities of [57Co]DOTATOC and [67Ga]DOTA-
TOC, the two radiopeptides show remarkably different 
biological behaviour, which we tend to assign to the different 
charge density of the metal ions. 
Conclusion 
[57Co]DOTATOC and [67Ga]DOTATOC are two 
radiopharmaceuticals which, despite their structural 
similarities (as shown by the X-ray structures of the model 
chelates CoII(H2DOTA) and GaIII(H2DOTA)+) display 
different biological behaviour. [57Co]DOTATOC presents the 
highest affinity for the sst2 subtype receptor of any 
radiometal-labelled somatostatin derivative. The improved 
receptor binding affinity is reflected in a high and specific 
tumour uptake and a high rate of internalisation. 
[57Co]DOTATOC has a relatively short tumour residence 
time in the AR4-2J animal model. This may not be a 
disadvantage if similar in humans as it leads to a low patient 
dose. In addition, its tumour-to-kidney ratio is one of the 
highest of any radiopeptide of the somatostatin analogues. 
Cobalt in [57Co]DOTATOC is present in the oxidation 
state of +2, as demonstrated in aqueous solutions of 
CoII(H2DOTA) and CoII(DOTA-D-PheNH2)-, and the 
coordination geometry of the CoII ion is a somewhat distorted 
octahedron. 
 This work illustrates how the physical features (size, 
charge) of the radiometal strongly influence the receptor 
affinity, biodistribution and pharmacokinetics of radiometal 
labelled peptides. Our results encourage further animal and 
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possibly clinical studies in order to evaluate the full potential 
of [55Co]DOTATOC as a PET agent.  
Experimental Section 
Chemicals and analysis: All chemicals were obtained from commercial sources and 
used without further purification. DOTA was a gift from Guerbet, France. 57CoCl2 was 
purchased from Isotope Products Laboratories, Burbank (CA), USA. Sephadex G-50 
(Pharmacia) was used for gel chromatography. Electrospray ionisation (ESI) was 
carried out with a Finnigan SSQ 7000 spectrometer. Analytical and semipreparative 
HPLC was performed on a Hewlett Packard 1050 HPLC system with a multiwavelength 
detector and a flow through Berthold LB 506 C1 γ-detector. Quantitative γ-counting 
was performed on a COBRA 5003 γ-system well counter from Packard Instrument 
Company. 1H/13C NMR was performed with either a Varian VXR 400 at 400/101 MHz 
or a Varian Unity 500 at 500/126 MHz. Chemical shifts reported are relative to TMS. 
59Co NMR was performed on a Bruker AV400 spectrometer at 94.939 MHz; 0.1 M 
K3[Co(CN)6] in D2O was used as an external reference and the presence of signals was 
checked between +15000 and -1000 ppm. 
Syntheses and labelling 
[DOTA0,Tyr3]-octreotide (DOTATOC) and GaIII-DOTATOC were synthesised as 
described previously[13]. 
[57Co]DOTATOC: [57Co]DOTATOC was prepared as follows: DOTATOC (10 µg, 7 
nmol) was dissolved in a sodium acetate buffer (20 µL, 0.4 M, pH 5.0). 57CoCl2 (43 
µCi) was added and the mixture heated at 95°C for 30 min. Quality control was 
performed with HPLC (Nucleosil 120-C18, M&N; eluents A = 0.1% TFA in H2O and B 
= CH3CN; gradient: 0-5 min 100% A, 25 min 75% A, 30-35 min 100% A). The 
labelling yield was >99.5%; the achieved specific activity was 5 mCi/µmol, which 
corresponds to a peptide-to-57Co ratio of 50:1. MS-ESI: m/z = 1477.3 [M-H]- (100%), 
1499.5 [M+HCOO-]- (20%), 1535.8 [M+CH3COO-]- (10%); purity (HPLC): > 97%. 
CoII(DOTA-D-PheNH2)-: CoII(DOTA-D-PheNH2)- was obtained from the reaction of 
DOTA-D-PheNH2 (8.0 mg, 14.5 µmol) with CoCl2 · 6 H2O (3.8 mg, 16 µmol) in 
aqueous solution (1 ml, pH 4, 95°C, 30 min). After cooling to room temperature the pH 
was adjusted to 5 with 0.1 M NaOH. Evaporation to dryness afforded a purple solid in 
quantitative yield. MS-ESI: C25H36CoN6O8 (M = 607.52 g/mol) m/z = 608.8 [M+H]+ 
(30%); 630.5 [M+Na]+ (20%); 606.4 [M-H]- (100%); 1H NMR (500 MHz, 25°C, D2O): 
δ = 6.9 (s, br, 2 H arom. ortho), 7.7 (m, 2 H arom. meta and 1 H arom. para); in the 2.25 
– 3.25 ppm range one detects three small broad signals (each one with an integration 
corresponding to 1 H). We checked for 1H NMR signals in a spectral window of +400 
to –400 ppm in the temperature range 5-90 oC. 59Co NMR spectroscopy (94.939 MHz, 
25 °C, D2O) showed no signals in a spectral window of +15000 to –1000 ppm. 
CoII(H2DOTA): CoII(H2DOTA) was obtained from the reaction of DOTA (50 mg, 0.12 
mmol) with CoCl2 · 6 H2O (28.6 mg, 0.12 mmol) in aqueous solution (5 ml, pH 4.8, 
95°C, 25 min). Slow evaporation produced light red single crystals suitable for X-ray 
analysis. MS-ESI: C16H26CoN4O8 (M = 461.11 g/mol) m/z = 462.1 [M+H]+ (100%); 1H 
NMR (400 MHz, 25°C, D2O): no signals were observed. 
GaIII(H2DOTA)+Cl-: GaIII(H2DOTA)+Cl’ was obtained from the reaction of DOTA 
(78.73 mg, 0.181 mmol) with Ga(NO3)3 ⋅ 9 H2O (91 mg, 0,217 mmol) in aqueous 
solution (5 ml, pH 4, 80°C, 30 min). After cooling at room temperature, the pH was 
adjusted to 8 with 0.1 M NaOH. Excess of GaIII (in the form of hydroxide) was filtered 
off and the final pH adjusted to 7 with 0.1 M HCl. Slow evaporation of water afforded 
colourless crystals suitable for X-ray diffraction. MS-ESI: C16H25GaN4O8 (M = 471.11 
g/mol), m/z = 471.1, 472.1(6:4) [M+H]+ (100%); Elemental analysis: 
C16H25N4O8Ga⋅HNO3⋅2H2O (M = 570.16 g/mol): theoretically C 33.71, H 5.30, N 12.29, 
O 36.47; found C 33.57, H 5.10, N 12.25, O 31.52; 1H-NMR: (400 MHz, 27°C, D2O): δ 
= 3.40 (s, br, 16 H, N-CH2-CH2-N), 3.68 (s, br, 8 H, N-CH2-COOD); 13C-NMR: (101 
MHz, 27°C, D2O, pD = 6.9): δ = 52.52 (N-CH2-CH2-N), 58.48 (N-CH2-COOGa), 
176.40 (COOGa); IR (KBr): ν = 3570, 3492, 2956, 2705, 2650, 2590, 1746, 1710, 1699, 
1620, 1496, 1475, 1384, 1339, 1316, 1287, 1240, 1212, 1083, 1047, 925 cm-1. 
Kinetic exchange 
The kinetic stability of [57Co]DOTATOC upon trans-chelation was determined using a 
104-fold excess of DTPA. [57Co]DOTATOC (6 µL, 10-11 mol) was mixed with DTPA 
(10 µl, 10-7 mol) and 484 µL 0.1 M NaOAc pH 5.0. The exchange rate of this solution 
was measured by taking aliquots (50 µL) and the exchange ratio [57Co]DOTATOC 
versus 57CoII(DTPA)3- was analysed by HPLC at time intervals of 4 to 24 h. 
In addition, the chemical inertness of [57Co]DOTATOC was verified by measuring the 
isotope exchange rate of the radiocobalt-labelled peptide versus a 104 excess of free 
59CoII. The experiment was carried out using similar concentrations of 
[57Co]DOTATOC and 59CoCl2 as described above. Aliquots of 50 µL were incubated 
with DTPA (10-3 M, 10 µL) prior to HPLC analyses to enable a detection of 57CoII as 
[57Co](DTPA)3- complex. 
Serum stability studies 
[57Co]DOTATOC was added to fresh human blood serum (1 µCi/mL) and incubated at 
37°C in a CO2 atmosphere (5%). At defined times aliquots of 50-100 µL were taken and 
analysed by gel-chromatography (Sephadex G50, PBS buffer 0.01 M, pH 7.4). Low- 
and high-molecular fractions were collected and measured with a γ-counter. The amount 
of serum protein-bound radiopeptide was calculated by the count rates of both fractions 
[32]
.  
Thermodynamic stability and protonation constants 
The thermodynamic stability constant of CoII(DOTA-D-PheNH2)- was estimated by 
competition experiments using DOTA as a competing chelator. For this purpose, 
solutions containing similar amounts of both ligands were used (0.01 M, 40  µL). 
57/59CoCl2 was added in phosphate-buffer (0.01 M, pH 7.0, 20 µL). The mixture was 
incubated at room temperature at controlled pH. Aliquots of 15  µL were taken at 
different times and analysed by HPLC equipped with a Berthold γ-detector (CC 250-4 
mm 120-3 C8, M&N, eluent: A = 0.1% TFA in H2O, B = CH3CN, 0-5 min 100% A, 25-
35 min 30% B, 35 min 100% A). 
The protonation constants of DOTA and DOTA-D-Phe-NH2 were obtained by 
potentiometric titration in a thermostated cell at 25°C under a stream of N2 with a 0.5 M 
solution of tetramethylammonium hydroxide (standardised with potassium 
hydrogenophtalate) at an ionic strength adjusted to 0.5 M with tetramethylammonium 
nitrate in a Metrohm 665-Dosimat equipped with a 1 mL piston burette.  Excess nitric 
acid was added to the ligand solutions to determine the lower protonation constants. All 
the solutions were prepared with deionised water (Millipore) which was previously 
boiled to remove the CO2. pH measurements were carried out with a Metrohm 645 
digital pH-meter equipped with a Metrohm 6.0204.100 glass electrode combined with a 
calomel (3 M KCl) reference electrode. The glass electrode was calibrated with pH 4.0 
and 7.0 buffers at 25°C. The pH meter/electrode system was calibrated by titration of a 
3.2 mM TRIS solution with 0.5 M tetramethylammonium hydroxide at an ionic strength 
adjusted to 0.5 M with tetramethylammonium nitrate. The data were handled and 
calculated with the program TITFIT[33]. 
Cell culture 
AR4-2J rat pancreatic tumour cells expressing sst2 were cultured in high glucose 
Dulbecco’s minimal essential medium (DMEM), enriched with 4 nM glutamine, 10% 
FBS, amino acids, vitamins and penicillin-streptomycin from BioConcept (Allschwil, 
Switzerland). Cells were maintained in a humidified 5% CO2/air atmosphere at 37°C. 
The viability of the cells was assessed using trypan blue stain and counted under a 
microscope with a “Neubauer’s counting chamber”. 
Receptor binding assays 
Cells stably expressing human sst1, sst2, sst3, sst4 and sst5 were grown as described 
previously[12]. All culture reagents were supplied by Gibco and Life Technologies 
(Grand Island, NY). Cell membrane pellets were prepared and receptor autoradiography 
was performed on pellet sections (mounted on microscope slides), as described in detail 
previously [12]. 
Complete displacement experiments were performed with the universal somatostatin 
radioligand 125I-[Leu8,D-Trp22,Tyr25]-somatostatin-28 (2000 Ci/mmol; Anawa, Wangen, 
Switzerland), using increasing concentrations of the unlabelled peptide ranging from 0.1 
to 1000 nM. Somatostatin-28 was run in parallel as control using the same increasing 
concentrations. IC50-values (inhibitory concentration 50%) were calculated after 
quantification of the data using a computer-assisted image processing system. Tissue 
standards (autoradiographic [125I]microscales, Amersham, UK) containing known 
amounts of isotopes, cross calibrated to tissue-equivalent ligand concentrations, were 
used for quantification[12]. The peptide concentration was measured by UV spectroscopy 
(ε280nm = 6849), according to the method of Reubi[12], and was based on the exact 
knowledge of the elemental analysis of [DOTA0,Tyr3]-octreotide. 
Internalisation and efflux studies 
Cells (106/well) were distributed in six-well plates at 37°C, in a 5% CO2/air atmosphere 
during one night in culture medium (DMEM with 10% FBS). The medium was 
removed; the cells were washed and incubated for 1 h, with internalisation medium 
(DMEM with 1% FBS) under the same conditions as described above. Approximately 
0.02 MBq/well of the radioligand (2.5 pmol/well) were added to the medium and the 
cells were incubated at 37°C, 5% CO2, with and without excess of peptide (1 µg) to 
determine non-specific internalisation. At appropriate time periods, the internalisation 
was stopped by removing the medium and washing the cells with ice cold PBS. To 
remove the receptor-bound radioligand an acid wash was carried out with a 0.1 M 
glycine buffer pH 2.8, during 10 min, on ice. This procedure permits to distinguish 
between membrane-bound (acid-releasable) and internalised radioligand (acid-resistant). 
Finally, cells were solubilised with 1 M NaOH and incubated for 10 min at 37°C. The 
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radioactivity of the culture medium, the receptor-bound and the internalised fractions 
were measured in a γ–counter (Cobra II, Packard Instr., Switzerland). 
For externalisation experiments the AR4-2J cells (106/well) were incubated with 2.5 
pmol/well of radioligand. After 2 h of internalisation at 37°C, 5% CO2, the medium was 
removed and the cells were washed twice with cold PBS. An acid wash was performed, 
as described in the previous section. Three millilitres of internalisation medium were 
added to each well and the cells were incubated at 37°C. At different time points the 
external medium was collected and exchanged with 37°C fresh medium. Thereafter, the 
cells were treated with 1 M NaOH to extract the internalised radioligand. The 
radioactivity of the external medium and of the internalised radioligand fractions was 
quantified in a γ–counter. The recycled fraction was expressed as percentage of the 
totally internalised amount per 1 million cells. 
Biodistribution studies in tumour-bearing animals 
All animal experiments were performed in compliance with the Swiss laws on animal 
protection (approval no. 789). Male nude mice (IFFACREDO, France) were injected 
subcutaneously in the right abdomen with a cell suspension of a rat pancreatic cell 
tumour (AR4-2J, 5 million cells/50 µL). Six to seven days post injection the tumours 
were grown to a size of approximately 0.5 cm in diameter. The animals were split into 
four groups: three batches of four animals without pre-treatment for 4 h, 24 h, and 48 h 
biodistribution studies; four animals which were injected with 50 µg Octreotide® 
together with the radiopharmaceutical. Both substances, the radioligand as well as 
Octreotide®, were prepared in a 0.1% bovine serum albumin solution in order to prevent 
sticking of the substances to the syringes. For the second tumour model five-week-old 
female Swiss athymic nude mice were implanted subcutaneously with 10 millions of 
HEK-sst2 cells on one flank. After 10-12 days the mice showed solid palpable tumour 
masses of 150-200 mg. In order to study the biodistribution of [57Co]DOTATOC, 3 µCi 
(120±15 kBq) of the radioligand was injected by the tail vein as a bolus into the tumour-
bearing mice. After the respective times the animals were sacrificed, a blood sample 
was taken, organs were removed, weighed, and the radioactivity was counted. 
X-ray diffraction studies 
The X-ray measurements of GaIII(DOTA)- and CoII(DOTA)2- were performed on a 
Nicolet P3 diffractometer with graphite-monochromatic Mokα-radiation. 
Crystallographic data are summarised in Table 4, average bond lengths, angles and 
planes in Table 5. The structures were solved using Patterson methods, expanded by 
Fourier techniques and refined against F2 by full-matrix least-squares methods using 
ShelX93 crystallographic software package[34]. Crystallographic data (excluding 
structure factors) for the structures of the gallium and the cobalt chelates have been 
deposited with the Cambridge Crystallographic Data Centre and allocated the 
deposition numbers CCDC 616729 & 616730, respectively. Copies of the data can be 
obtained free of charge on application to the director, CCDC, 12 Union Road, 
Cambridge CB2 1EZ, (fax: (+44) 1223-336-033, e-mail: deposit@ccdc.cam.ac.uk).  
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Legends to the figures 
 
 
Figure 1. Structural formulae of [DOTA0,Tyr3]-octreotide (DOTATOC) (above) and DOTA-D-PheNH2 
(below). 
 
Figure 2. Typical HPLC-radiochromatogram of a 1:1:1 mixture of 57,59CoCl2:DOTA:DOTA-D-PheNH2 
(0.1 M NaOAc, pH 5.0) after 9 days of incubation at RT. 
 
Figure 3. Internalisation (triangles; scales on the left side and bottom) and externalization (diamonds; 
scales on the right side and top) of [57Co]DOTATOC in rat pancreatic AR4-2J cells. 
 
Figure 4. Biodistribution of [57Co]DOTATOC on nude mice bearing a tumour (% IA/g: % injected 
activity per gram). 
 
Figure 5. Ortep plot of the crystal structure of CoII(DOTA)2- (thermal ellipsoids at 50% probability level). 
Selected bond lengths [Å] and angles [°]: Co(1)-N(2) 2.271(6), Co(1)-N(2) 2.271(6), Co(1)-N(3) 
2.203(6), Co(1)-N(3) 2.203(6), Co(1)-O(5) 2.038(5), Co(1)-O(5) 2.038(5); N(2)-Co(1)-N(2) 108.1(3), 
N(3)-Co(1)-N(3) 154.0(3), O(5)-Co(1)-O(5) 90.7(3). 
 
Figure 6. Ortep plot of the crystal structure of GaIII(DOTA)- (thermal ellipsoids at 50% probability level). 
Selected bond lengths [Å] and angles [°]: Ga(1)-N(3) 2.105(9), Ga(1)-N(5) 2.116(9), Ga(1)-N(2) 
2.116(10), Ga(1)-N(4) 2.187(10), Ga(1)-O(8) 1.940(7), Ga(1)-O(12) 1.913(8); N(3)-Ga(1)-N(5) 109.0(2), 
O(12)-Ga(1)-O(8) 82.39(13), N(2)-Ga(1)-N(4) 157.1(2). 
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Figure 1. Structural formulae of [DOTA0,Tyr3]-octreotide (DOTATOC) (above) and DOTA-D-PheNH2 
(below). 
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Figure 2. Typical HPLC-radiochromatogram of a 1:1:1 mixture of 57,59CoCl2:DOTA:DOTA-D-PheNH2 
(0.1 M NaOAc, pH 5.0) after 9 days of incubation at RT. 
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Figure 3. Internalisation (triangles; scales on the left side and bottom) and externalization (diamonds; 
scales on the right side and top) of [57Co]DOTATOC in rat pancreatic AR4-2J cells. 
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Figure 4. Biodistribution of [57Co]DOTATOC on nude mice bearing a tumour (% IA/g: % injected 
activity per gram). 
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Figure 5. Ortep presentation of the X-ray structure CoII(DOTA)2- (thermoparameter with 50% 
probability). Selected bond lengths [Å] and angles [°]: Co(1)-N(2) 2.271(6), Co(1)-N(2) 
2.271(6), Co(1)-N(3) 2.203(6), Co(1)-N(3) 2.203(6), Co(1)-O(5) 2.038(5), Co(1)-O(5) 2.038(5); 
N(2)-Co(1)-N(2) 108.1(3), N(3)-Co(1)-N(3) 154.0(3), O(5)-Co(1)-O(5) 90.7(3). 
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Figure 6. Ortep presentation of the X-ray structure GaIII(DOTA)- (thermoparameter with 50% 
probability). Selected bond lengths [Å] and angles [°]: Ga(1)-N(3) 2.105(9), Ga(1)-N(5) 
2.116(9), Ga(1)-N(2) 2.116(10), Ga(1)-N(4) 2.187(10), Ga(1)-O(8) 1.940(7), Ga(1)-O(12) 
1.913(8); N(3)-Ga(1)-N(5) 109.0(2), O(12)-Ga(1)-O(8) 82.39(13), N(2)-Ga(1)-N(4) 157.1(2). 
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Improved pharmacokinetics and 
tumour targeting of a DOTA-
conjugated somatostatin analogue was 
achieved by its coupling to the 
positron emitter 55Co (57Co). The 
structural features of the (radio)metal 
complex determine in vivo properties. 
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